SUO 2019 non-invasive assay for Upper tract urothelial carcinoma detection, prognostic utility of cfDNA, urinary markers, droplet digital polymerase chain reaction (ddPCR) assay
Ping Mu discusses his team’s paper, “ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity in AR-Targeted Therapy Resistance in Prostate Cancer,” published in Cancer Discovery. Dr. Mu…
Benign Prostatic Obstruction (BPO), benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), UrOP (Urologi Ospedalità Gestione Privata), Leonardi Ejaculation Sparing Technique (LEST), Aquablation, Rezum,…
Alicia Morgans speaks with Mary-Ellen Taplin about strategies for managing metastatic hormone-sensitive prostate cancer (mHSPC) patients who do not achieve optimal PSA declines. Dr. Taplin…
Ruchika Talwar interviews Aaron Gurayah and Raveen Syan about their study on pelvic floor disorders among minority women. The research highlights that while these disorders…
Invasive cribriform pattern 4 carcinoma (CC), Intraductal Prostatic Carcinoma, intraductal carcinoma (IDC), PSA level, Gleason score, positive surgical margin, seminal vesicle invasion, extraprostatic extension, lymph…
ureteric stent, ureteric stents on strings (SOS), Post-Ureteroscopy Ureteric Drainage, stone disease. standard ureteric stents without strings (SWOS),
Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly…
TROPiCS-02 trial, Sacituzumab govitecan, TROPHY-U-01 phase 2 trial, TROPiCS-04 trial, TROP2 targeting antibody drug conjugates in clinical trials,
Rashid Sayyid and Zach Klaassen dissect the EV-302 trial, presenting enfortumab vedotin and pembrolizumab as a first-line treatment for advanced urothelial cancer. This trial, marked…
Leslie Ballas hosts a discussion with Kent Mouw, who shares findings from his team’s publication in European Urology on the preclinical effects of combining enfortumab…
